As a pioneer in particle analysis, we are revolutionizing the industry with breakthrough developments and creating an innovative, efficient process that increases quality, safety and cost effectiveness.
We enable faster medicinal development and ensure that both the time and expense in medicinal development can be significantly reduced – while simultaneously increasing quality, production and patient safety.
Bionter’s Executive Team
Bionter’s management team consists of renowned experts in the field of biopharmaceutical industry and particle testing, holding both research and entrepreneurial backgrounds. Together with our collaboration partners, we are working on the idea of improving drug development and quality control. With current as well as future developments within the bioprocess workflow, we aim at making a significant contribution to patient safety and to improve human health.
Founder and CEO of Bionter. He holds a Ph.D. in pharmaceutical sciences and has a long record of inventing and developing innovative devices in the pharmaceutical sector.
In July 2020, he launched his company, Bionter, with the purpose of making the many steps of the drug development process more efficient, and thus ultimately improving people’s health. As a biotechnologist and chemist, he has a deep understanding of technology; his professional experience in drug product development helps him understand the needs of this market; his analytical and creative mindset helps him to exceed current processes and mindsets.
“In any business setting, a careful observer tries to find equipment and processes that can be improved. This was and remains exactly my goal: helping other scientists develop medicines faster and better.”
CEO & Board Member at ten23 health. He is a pharmacist by training and holds a Ph.D. in pharmacology and toxicology.
In 2015, he was appointed Associate Professor at the University of Frankfurt and teaches at the University of Frankfurt and at the University of Basel. Mahler has previously held leading positions at Lonza AG, Fa Hoffmann-La Roche Ltd and Merck KGaA. He has an extensive expertise in particle testing, process development & validation, and regulatory submissions.
Reinhard Vogt is an experienced C-level leader and former Executive Vice President at Sartorius. Vogt holds in-depth knowledge of customer needs, technology, sales and production in the Biotech sector.
Since March 2021, Marc Funk has been CEO of Recipharm, a contract manufacturer and developer for the pharmaceutical industry. Prior to that, Funk held C-level positions at Lonza.
Angelika Schrems is Head of Business Development at Bionter. She has more than 10 years of experience in business development in various industries. She holds a PhD in Biotechnology and an MBA in strategic management.
Shahbaz Arif is a scientist at Bionter. He has more than 7 years of experience in Pharma research and analytical testing. He is well-connected in the particle testing community.
Professor John Carpenter of the University of Denver, Colorado, supports Bionter as one of the world’s leading scientists in particle testing. Dr. Carpenter is an expert in the field of protein aggregation.
What we believe in
Bionter is based on three simple values. We share them among ourselves and those we partner and do business with.